Efficacy and Safety Study of the Fixed-dose Combination of Olmesartan + Indapamide When Compared to the Isolated Drugs in the Treatment of Hypertension.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 400 participants.

Also called NCT05110898

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 400 participants (planned count) (from the registry)
Sponsor
Brainfarma Industria Química e Farmacêutica S/A (from the registry)
Registry
  • NCT NCT05110898
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05110898. Randomized; single masking; primary purpose treatment. Start 2022-08-01 (anticipated); primary completion 2023-08-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety Study of the Fixed-dose Combination of Olmesartan + Indapamide When Compared to the Isolated Drugs in the Treatment of Hypertension.
Acronym
OLINDA
Condition
Hypertension
Condition
Hypertension,Essential
Intervention (Drug)
fixed-dose of olmesartan 20mg/40 mg + indapamide 1,5 mg
Intervention (Drug)
Isolated drugs Olmesartan (20 mg or 40 mg) and Indapamide (1,5 mg)
Lead sponsor
Brainfarma Industria Química e Farmacêutica S/A (class: industry)

Record details

Record id
cardio:ct-nct05110898
Content hash
4a7f91c93e244f2d8fcd5dc20890ee7190156e806a17b5293e7022664436942c